UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
FORM 8-K
CURRENT REPORT
Pursuant to Section 13 or 15(d)
of the Securities Exchange Act of 1934.
Date of Report: May 10, 2016
(Date of earliest event reported)
Oragenics, Inc.
(Exact name of registrant as specified in its charter)
FL | 001-32188 | 59-3410522 | ||
(State or other jurisdiction of incorporation) |
(Commission File Number) |
(IRS Employer Identification Number) |
4902 Eisenhower Boulevard, Suite 125 Tampa, FL |
33634 | |
(Address of principal executive offices) | (Zip Code) |
813-286-7900
(Registrants telephone number, including area code)
Not Applicable
(Former Name or Former Address, if changed since last report)
Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:
¨ | Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425) |
¨ | Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12) |
¨ | Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b)) |
¨ | Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c)) |
Item 3.01. | Notice of Delisting or Failure to Satisfy a Continued Listing Rule or Standard; Transfer of Listing. |
On May 10, 2016, Oragenics, Inc. (the Company) received notification (the Deficiency Letter) from the NYSE MKT LLC that it is not in compliance with certain NYSE MKT continued listing standards relating to stockholders equity as of December 31, 2015. Specifically, the Company is not in compliance with Section 1003(a)(iii) (requiring stockholders equity of $6.0 million or more if it has reported losses from continuing operations and/or net losses in its five most recent fiscal years). As of December 31, 2015, the Company had stockholders equity of $4.7 million. The Company is required to submit a plan to the NYSE MKT by June 10, 2016 advising of actions it has taken or will take to regain compliance with the continued listing standards by November 10, 2017. The Company intends to submit a plan by the June 10, 2016 deadline. If the Company fails to submit a plan, or if the Companys plan is not accepted or if the Company fails to regain compliance by the deadline, the NYSE MKT may commence delisting procedures.
The Companys common stock will continue to be listed on the NYSE MKT while it attempts to regain compliance with the listing standards noted, subject to the Companys compliance with other continued listing requirements. The Companys common stock will continue to trade under the symbol OGEN, but will have an added designation of .BC to indicate that the Company is not in compliance with the NYSE MKTs listing standards. The NYSE MKT notification does not affect the Companys business operations or its SEC reporting requirements and does not conflict with or cause an event of default under any of the Companys material agreements.
The Company issued a press release on May 13, 2016, announcing that it had received the notice of noncompliance. A copy of the press release is attached to this Current Report on Form 8-K as Exhibit 99.1.
Item 9.01 | Financial Statements and Exhibits. |
(d) | Exhibits |
Exhibit |
Description | |
99.1 | Press release, dated May 13, 2016, regarding NYSE MKT notice of non-compliance |
SIGNATURES
In accordance with the requirements of the Exchange Act, the registrant caused this report to be signed on its behalf by the undersigned, thereunto duly authorized on this 13th day of May 2016.
ORAGENICS, INC. (Registrant) | ||
BY: |
/s/ Michael Sullivan | |
Michael Sullivan Chief Financial Officer |